Trial Profile
A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, REPEATED DOSE, THREE-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF TWO DOSES OF CHF 6001 DPI IN SUBJECTS WITH MODERATE, SEVERE COPD.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tanimilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 17 Jan 2018 Status changed from recruiting to completed.
- 08 Dec 2016 New trial record